SCHEMBL24916702

SCHEMBL24916702

COc1ccc(-c2cnc3c(Nc4ccc(C(=O)N(C)CCOCCN5CCOCC5)c(C)c4)nccn23)cc1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPKAPK5 Q8IW41 3/20 0.47
▸ MAPK1 P28482 1/20 0.42
▸ CD274 Q9NZQ7 1/20 0.40
▸ FYN P06241 1/20 0.39
▸ JAK3 P52333 2/20 0.39
▸ BTK Q06187 2/20 0.39
▸ FLT1 P17948 2/20 0.38
▸ FLT4 P35916 2/20 0.38
▸ TEK Q02763 2/20 0.38
▸ STK10 O94804 1/20 0.38
▸ CSF1R P07333 1/20 0.38
▸ RET P07949 1/20 0.38
▸ PDGFRB P09619 1/20 0.38
▸ KIT P10721 1/20 0.38
▸ AXL P30530 1/20 0.38
▸ TIE1 P35590 1/20 0.38
▸ FLT3 P36888 1/20 0.38
▸ MERTK Q12866 1/20 0.38
▸ EGFR P00533 4/20 0.38
▸ KDR P35968 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24917117 0.93 PTK6 (0.44) MAPKAPK5EGFRPTK6TTKAURKA
SCHEMBL22124591 0.92 MAPKAPK5 (0.41) MAPKAPK5MAPK1FYNFLT1FLT4
SCHEMBL30349964 0.92 MAPKAPK5 (0.41) MAPKAPK5MAPK1FYNFLT1FLT4
SCHEMBL22124685 0.92 MAPKAPK5 (0.40) MAPKAPK5MAPK1JAK3RETPTK6
SCHEMBL22124669 0.92 MAPKAPK5 (0.40) MAPKAPK5MAPK1AXLKDRPTK6
SCHEMBL22125014 0.91 MAPKAPK5 (0.42) MAPKAPK5CD274FYNEGFRPTK6
SCHEMBL30349738 0.91 MAPKAPK5 (0.42) MAPKAPK5CD274FYNEGFRPTK6
SCHEMBL22124676 0.91 TTK (0.39) MAPKAPK5MAPK1AXLPTK6TTK
SCHEMBL22124850 0.91 MAPKAPK5 (0.41) MAPKAPK5MAPK1KDRPTK6TTK
SCHEMBL25170323 0.88 MAPKAPK5 (0.40) MAPKAPK5PTK6TTKAURKAAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230017532-A1 NOVEL IMIDAZOPYRAZINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2023-01-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230017532-A1 NOVEL IMIDAZOPYRAZINE DERIVATIVES MRPL21, O60361, MYD88 MAPKAPK5 695/4885MAPK1 320/4885CD274 3787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback